Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Abstract: Methods, compositions, and devices for transdermally administering an active agent such as donepezil are provided. In one aspect, the method comprises contacting skin with a transdermal device designed to create a depot of the active agent in the subject, removing the transdermal device and continuing to administer the active agent for a period after the device is removed.

Abstract: Embodiments are disclosed for submersion detection and underwater depth and low-latency temperature estimation. In an embodiment, a method comprises: determining a first set of vertical accelerations obtained from an inertial sensor of a wearable device; determining a second set of vertical accelerations obtained from pressure data; determining a first feature associated with a correlation between the first and second sets of vertical accelerations; and determining that the wearable device is submerged or not submerged in water based on a machine learning model applied to the first feature. In another embodiment, a method comprises: determining a submersion state of a wearable device; and responsive to the submersion state being submerged, computing a forward estimate of water temperature based on measured ambient water temperature at the water surface, a temperature error lookup table, and a rate of change of the ambient water temperature.

Abstract: Methods, compositions, and devices for transdermally administering an active agent such as donepezil are provided.

Abstract: A transdermal delivery system is described, where the system comprises a drug reservoir layer comprising an active agent and a skin contact adhesive layer. A microporous membrane that has been pretreated with a membrane treatment composition before the membrane is incorporated into the system is disposed between the drug reservoir layer and the skin contact adhesive layer.

Abstract: Technologies for low-leakage and low series resistance on-chip capacitors are disclosed. In the illustrative embodiment, each electrode of a capacitor is formed from two metal layers and vias between the metal layers. A high-k dielectric layer is between the metal layers. The electrodes are displaced relative to each other on the plane defined by the high-k dielectric layer. As a result, electric field lines of the capacitor are parallel to the high-k dielectric layer. The electrodes can be displaced from each other by more than the thickness of the high-k dielectric layer, reducing the leakage current through the high-k dielectric layer as compared to a capacitor with field lines perpendicular to the high-k dielectric layer. Such a capacitor may be used to provide power to circuits in a low-power state with little leakage current and/or may be used to absorb radiofrequency (RF) interference.

Abstract: An apparatus, system, and method for improved thermal design power (TDP) range are provided. A device includes a first voltage regulator configured to provide first voltage of a first voltage value, a second voltage regulator configured to provide a second voltage of a second, different voltage value, a first capacitor electrically coupled between a first output of the first voltage regulator and a ground, a second capacitor electrically coupled between a second output of the second voltage regulator and the ground, a first switch electrically coupled between the first output and the second output, a second switch situated in parallel with the first switch, the second switch electrically coupled between the first output and the second output, and a controller configured to provide control signals that control the first voltage regulator, the second voltage regulator, the first switch, and the second switch.

Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Abstract: Embodiments herein relate to a feedback loop in a digital voltage regulator for controlling an output voltage. To avoid instability at light current loads, a gain of the loop is reduced as a power gate code indicates a reduced number of branches in set of current sources are enabled. In an example implementation, the code is classified into one range of a number of ranges, and the gain is set based on the one range. The gain can decrease each time the code enters a lower range, as indicated by the code crossing a threshold or predetermined value. For example, the gain can decrease by half each time the code enters a lower range.

Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Abstract: An adhesive matrix and adhesive formulation are described. The adhesive matrix is comprised of a hydrophilic domain and a hydrophobic domain, and a therapeutically active agent contained in the matrix in a supersaturated, stable, condition. The hydrophilic domain and the hydrophobic domain are co-soluble in a solvent system, to provide a homogeneous blend in which the active agent is solubilized. The proportion of the hydrophilic domain and hydrophobic domain is selected to optimize, or maximize, solubility of active agent in the matrix.

Abstract: A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

Abstract: An adhesive matrix and adhesive formulation are described. The adhesive matrix is comprised of a hydrophilic domain and a hydrophobic domain, and a therapeutically active agent contained in the matrix in a supersaturated, stable, condition. The hydrophilic domain and the hydrophobic domain are co-soluble in a solvent system, to provide a homogeneous blend in which the active agent is solubilized. The proportion of the hydrophilic domain and hydrophobic domain is selected to optimize, or maximize, solubility of active agent in the matrix.

Abstract: Techniques and mechanisms for determining an operational mode of a voltage regulator. In an embodiment, an integrated circuit (IC) die is coupled to receive power from a voltage regulator (VR) via a power delivery network (PDN) which comprises circuitry in or on a substrate, such as that of a printed circuit board. The IC die receives from the substrate information indicating a characteristic of a parasitic impedance at the substrate. Based on the information, a controller unit at the IC die selects one of multiple VR modes which each correspond to a respective one of different parasitic impedance characteristics. The controller then signals the VR to provide the selected mode. In an embodiment one of the VR modes corresponds to a relatively high impedance, and also corresponds to a relatively stable sensitivity function in a frequency range above a control bandwidth.

Abstract: An apparatus is provided which comprises: a first voltage regulator; a second voltage regulator; and a switch to selectively couple the first voltage regulator to the second voltage regulator, such that a first output node of the first voltage regulator is temporarily coupled to a second output node of the second voltage regulator via the switch.

Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Abstract: Methods, compositions, and devices for transdermally administering an active agent such as memantine are provided.

Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.